Nanobiotix (NANO.PA) Sees a Surge in Share Price Amid a Robust Trading Day
Nanobiotix, the French‑based late‑stage clinical biotechnology company, closed its trading session on Wednesday, 21 October 2026, with a notable 12.47 % jump in share price. The last closing price stood at EUR 24.06 per share, a significant lift from the previous session. With a current market capitalisation of EUR 938.5 million, the firm’s valuation reflects investor confidence in its physics‑based therapeutic platform.
Trading Metrics
| Item | Value |
|---|---|
| Current price | EUR 24.06 |
| Shares outstanding | 50.5 million |
| Market capitalisation | EUR 938.5 million |
| 24‑hour trading volume | EUR 3.9 million |
| 24‑hour change | +12.47 % |
| 200‑day simple moving average | EUR 28.87 |
| 52‑week high | EUR 47.66 (18 May 2026) |
| 52‑week low | EUR 13.10 (28 Oct 2025) |
| Month‑end change | –28.52 % |
The spike in share value came after a routine corporate announcement that reaffirmed the company’s stable share and voting‑right structure. Nanobiotix reported 50.9 million shares outstanding and 54.7 million voting rights in a filing dated 20 October 2026, underscoring the absence of any significant dilution or governance shift.
Corporate Focus and Portfolio
Nanobiotix remains dedicated to its core mission: revolutionising cancer treatment by amplifying the impact of radiotherapy within tumour cells while sparing adjacent healthy tissue. Its flagship platform, NanoXray, employs engineered nanoparticles to deliver radiation directly to malignant cells. The company’s product pipeline includes:
- NBTXR3 – a preclinical research program centred on cancer immunotherapies.
- A portfolio of over 30 patent families covering three distinct nanotechnology platforms.
With a presence on both Euronext Paris and Nasdaq, Nanobiotix continues to attract global investors interested in cutting‑edge biopharmaceutical solutions.
Comparative Performance of Peer Stocks
The 24‑hour trading results for several related equities are as follows:
| Stock | 24‑hour change | Current price (EUR) | Market capitalisation (EUR) | Notes |
|---|---|---|---|---|
| Gl Events (GLO.PA) | +3.65 % | 32.45 | 943.8 million | PE ratio 11.03 |
| Fnac Darty (FNAC.PA) | +0.72 % | 34.85 | 1 billion | Subject to EP Group takeover proposal |
| North Atlantic Energies (NAE.PA) | –0.72 % | 74.15 | 975 million | |
| Altareit (AREIT.PA) | 0 % | 555 | 971.4 million | |
| Electricité de Strasbourg (ELEC.PA) | +0.90 % | 157.4 | 1.1 billion | PE ratio 8.54 |
Takeover Activity: Fnac Darty
A noteworthy development in the broader market is the formal takeover proposal for Fnac Darty by EP Group. The proposal, approved by the French regulatory authority after European Commission clearance, offers a fixed premium for ordinary shares and a separate consideration for OCEANEs. The board of Fnac Darty has expressed a favourable opinion, and an independent valuation confirms the fairness of the terms for shareholders and OCEANE holders. The offer will remain open for an additional ten trading days, contingent on the acquisition of a requisite ownership threshold, after which the final outcome will be disclosed by the financial markets authority.
Outlook
While Nanobiotix’s recent rally highlights market enthusiasm for its innovative nanomedicine approach, the broader context—particularly the month‑end decline of –28.52 %—suggests a volatile environment for the company’s shares. Investors will likely monitor upcoming clinical trial milestones and regulatory filings closely, as these developments will shape the firm’s future valuation and market trajectory.
